Making End HIV Epidemic targets achievable and fair across communities
Are Ending the HIV Epidemic goals attainable across race/ethnic groups, risk groups, and settings?
['FUNDING_R01'] · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · NIH-11192375
Using computer models and local health data, this project aims to find how best to spread HIV prevention and treatment so people in different racial groups, risk groups, and places can meet End HIV Epidemic goals.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NEW YORK UNIVERSITY SCHOOL OF MEDICINE (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11192375 on ClinicalTrials.gov |
What this research studies
The team will combine data from local health departments in New York City, Shelby County (Memphis), and northwest Mississippi with mathematical simulations to compare ways of distributing prevention and treatment resources. The models will include screening and responses for alcohol, substance use, and mood conditions and will simulate new long-acting injectable PrEP and ART options. Local partners will advise on real-world feasibility and acceptability so the scenarios reflect community needs. The researchers will also explore trade-offs between maximizing overall benefit and spreading improvements more evenly across vulnerable subgroups.
Who could benefit from this research
Good fit: People living with HIV, people at risk for HIV, and community members in New York City, Shelby County (Memphis), or northwest Mississippi/Arkansas are the most relevant groups for this work.
Not a fit: People who live outside the targeted regions or who are not at risk for HIV are unlikely to see direct benefits from this specific project.
Why it matters
Potential benefit: If successful, this work could help public health programs reduce new HIV infections and make prevention and care fairer across racial and geographic groups.
How similar studies have performed: Mathematical modeling has previously guided HIV policy and resource choices, but combining alcohol/substance/mood screening, equity-focused trade-offs, and long-acting injectables is a newer approach.
Where this research is happening
NEW YORK, UNITED STATES
- NEW YORK UNIVERSITY SCHOOL OF MEDICINE — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BRAITHWAITE, RONALD SCOTT — NEW YORK UNIVERSITY SCHOOL OF MEDICINE
- Study coordinator: BRAITHWAITE, RONALD SCOTT
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus, Affective Disorders